Related Experiment Videos

[Kidney function and the effectiveness of hypotensive therapy of patients with hypertension]

Terapevticheskii Arkhiv
|January 1, 1986
PubMed

Insights

Detecting specific carbonic esterase isoenzymes (CE5-7) in urine indicates poor prognosis for hypertension patients with ischemic renal lesions. Certain blood pressure medications improved outcomes, unlike propranolol.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Chemistry

Background:

  • Hypertension is a major risk factor for ischemic renal lesions.
  • Early diagnosis and appropriate treatment are crucial for managing hypertensive nephropathy.
  • Carbonic esterases (CE) and their isoenzymes play roles in renal physiology and pathology.

Purpose of the Study:

  • To investigate the diagnostic and prognostic value of slow carbonic esterase isoenzymes (CE5-7) in urine for ischemic renal lesions in hypertensive patients.
  • To evaluate the impact of different antihypertensive medications on renal outcomes in these patients.

Main Methods:

  • Diagnosis of ischemic renal lesions in 108 hypertensive patients.
  • Urine analysis for the detection of slow carbonic esterase isoenzymes (CE5-7).
  • Assessment of therapeutic outcomes with various antihypertensive drugs, including propranolol and others affecting renal blood flow.

Main Results:

  • Detection of urinary carbonic esterase isoenzymes (CE5-7) was a poor prognostic indicator.
  • Propranolol use was associated with deteriorating renal circulation.
  • Antihypertensive drugs that did not impair or improved renal blood flow (e.g., dopegyt, chlophelin, reserpine, apressin, corinfar, isoptin) showed more promising results.

Conclusions:

  • Urinary CE5-7 isoenzymes are valuable markers for poor prognosis in hypertensive patients with ischemic renal lesions.
  • Medication choice is critical; drugs improving renal blood flow are preferred over those potentially worsening it, such as propranolol.

Related Concept Videos